These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3861196)

  • 21. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
    Kawano F; Tejima Y; Tajima H; Lee SY; Shiozaki A; Nakai R; Chyosa M; Sawada T; Maeda Y; Mizokuni T
    Rinsho Ketsueki; 1986 Mar; 27(3):315-20. PubMed ID: 3461178
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute leukemia in adults: assessment of remission induction with combination chemotherapy by clinical and cell-culture criteria.
    Curtis JE; Cowan DH; Bergsagel DE; Hasselback R; McCulloch EA
    Can Med Assoc J; 1975 Aug; 113(4):289-94. PubMed ID: 1056807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
    Barone S; Baer MR; Sait SN; Lawrence D; Block AW; Wetzler M
    Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does it matter how remission is achieved in acute leukemia?
    Bishop JF
    Leukemia; 1996 Apr; 10 Suppl 1():S7-9. PubMed ID: 8618474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Preliminary studies on the effectiveness of the association cytosine-arabinoside, thioguanine, hydroxyureas in the treatment of blastic crisis in chronic myeloid leukemia].
    Papa G; Amadori S; Monarca B; Alimena G; Esposito A; Mandelli F
    Haematologica; 1972; 58(9):597-600. PubMed ID: 4206235
    [No Abstract]   [Full Text] [Related]  

  • 27. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
    Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
    J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
    Minderman H; O'Loughlin KL; Smith PF; Pendyala L; Greco WR; Sweeney KG; Ford LA; Wetzler M; Baer MR
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):73-83. PubMed ID: 16010591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Principles of high-dose cytarabinoside treatment].
    Seeber S
    Onkologie; 1985 Feb; 8(1):4-7. PubMed ID: 3885120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
    Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
    Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB
    Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged high dose ARA-C infusions in acute leukemia.
    Spriggs DR; Robbins G; Arthur K; Mayer RJ; Kufe D
    Leukemia; 1988 May; 2(5):304-6. PubMed ID: 3287017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
    Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
    Br J Haematol; 1992 Oct; 82(2):337-46. PubMed ID: 1419816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro.
    Katagiri T; Miyazawa K; Nishimaki J; Yaguchi M; Kawanishi Y; Ohyashiki K
    Leuk Lymphoma; 2000 Sep; 39(1-2):173-84. PubMed ID: 10975397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensified therapy for acute myeloid leukemia.
    Bishop JF
    N Engl J Med; 1994 Oct; 331(14):941-2. PubMed ID: 8078557
    [No Abstract]   [Full Text] [Related]  

  • 36. [Successful treatment with low-dose Ara-C in a case of chronic myelomonocytic leukemia].
    Gotoh T; Takeda N; Itoh K; Fujita N; Shimazaki C; Nakanishi S; Nakagawa M; Ijichi H; Nishio A; Haruyama H
    Rinsho Ketsueki; 1987 Apr; 28(4):583-8. PubMed ID: 3476766
    [No Abstract]   [Full Text] [Related]  

  • 37. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
    Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
    Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment with low dose Ara-C in de novo acute myeloid leukemia with trilineage myelodysplasia.
    Kawano F; Nishimura Y; Tsukamoto A; Satoh M; Sanada I; Shido T
    Int J Hematol; 1992 Feb; 55(1):101-2. PubMed ID: 1581580
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
    Richel DJ; Colly LP; Lurvink E; Willemze R
    Br J Cancer; 1988 Dec; 58(6):730-3. PubMed ID: 2465015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
    Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
    Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.